Plain-English translation of NCT05568498 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Ecologic® BARRIER 849, a probiotic supplement containing beneficial bacteria, can help improve depression and mood in people living with Parkinson's disease. Depression affects about one-third of people with Parkinson's, and research suggests that the bacteria in our gut may influence mood. The study will compare this medication to a placebo (an inactive look-alike) to see if it truly makes a difference.
People with Parkinson's disease experience depression much more often than the general population, which significantly worsens their quality of life. Recent scientific evidence suggests that the helpful bacteria in our digestive system may play an important role in mood, so researchers want to test whether this treatment could offer a new way to help.
You likely qualify if…
You likely don't qualify if…
You would take a daily supplement (either the probiotic or placebo, given as a powder in a sachet twice daily) for the duration of the study. Neither you nor the researchers will know which group you're in, which helps ensure a fair test. You'll need to visit the research clinic for screening and baseline visits, and then continue with follow-up appointments to monitor how you're doing and whether your mood improves.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Canada